Press Releases
The latest news from StrideBio.
StrideBio Announces Achievement of Significant Operational Milestones Supporting Transition of Novel Gene Therapy Pipeline to Clinical Stage
100th team member hired, bolstering internal capabilities from capsid platform to clinic with an emphasis on in-house manufacturing capability Completed construction of GMP manufacturing facility ...
StrideBio Expands Leadership Team with Accomplished Industry Executives
Newly created roles will support StrideBio’s operations across strategy, regulatory affairs, quality, and patient advocacy Research Triangle Park, N.C., June 15, 2021 – StrideBio, Inc., ...
StrideBio Appoints Deborah D. Ascheim, M.D. as Chief Medical Officer
Research Triangle Park, N.C., April 27, 2021 – StrideBio, Inc., a leading developer of novel adeno-associated viral (AAV) based gene therapies, today announced the appointment ...
StrideBio Announces a Multi-technology License and Master SRA with Duke University to Advance Next-generation Gene Therapies
StrideBio receives exclusive license to novel cross-species evolved AAV vectors and an enzymatic approach for neutralizing antibody evasion Master Sponsored Research Agreement will support collaborative ...
StrideBio Announces Closing of $81.5M Series B Financing
Proceeds to advance structure-guided AAV capsid engineering platform and pipeline of novel gene therapy candidates into the clinic, including four new wholly-owned programs Financing will ...
StrideBio Expands Leadership Team with Appointment of William Monteith as Chief Operating Officer
Research Triangle Park, N.C., August 11, 2020 – StrideBio, Inc, a leading developer of novel engineered adeno-associated virus (AAV) based gene therapies, today announced the ...
StrideBio Appoints Maritza McIntyre, Ph.D., as Chief Development Officer
StrideBio, Inc., a leading developer of novel adeno-associated viral (AAV) based gene therapies, today announced the appointment of Maritza McIntyre, Ph.D., as Chief Development Officer.
Sarepta and StrideBio Announce Multi-target Strategic Collaboration to Advance Novel Gene Therapies
Sarepta Therapeutics, Inc. (NASDAQ: SRPT), the leader in precision genetic medicine for rare diseases, and StrideBio, Inc., a leading developer of novel adeno-associated viral (AAV) based gene therapies, today announced the signing of a collaboration and license agreement to develop in vivo AAV-based therapies for up to eight central nervous system (CNS) and neuromuscular targets.
StrideBio and Takeda Sign Collaboration and License Agreement to Advance Novel Gene Therapies for Neurological Diseases
StrideBio, Inc, a leading developer of novel adeno-associated viral (AAV) based gene therapies, today announced the signing of a collaboration and license agreement with Takeda Pharmaceutical Company Limited (Takeda) to develop in vivo AAV based therapies for Friedreich’s Ataxia (FA) and two additional undisclosed targets.
CRISPR Therapeutics and StrideBio Expand Exclusive Development and Option Agreement
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, and StrideBio, Inc., a leading developer of novel adeno-associated viral (AAV)-based gene therapies, today announced that a strategic collaboration, previously initiated in April 2017 to generate engineered AAV capsids with improved properties for in vivo gene editing programs, has now been expanded to include additional undisclosed applications.
StrideBio Appoints Sapan Shah, Ph.D. as Chief Executive Officer
StrideBio, Inc, a leading developer of novel adeno-associated viral (AAV) based gene therapies, announced today that the Board of Directors has appointed Sapan Shah, Ph.D. as Chief Executive Officer and a member of the company’s board.
StrideBio Closes $15.7 Million Series A Financing to Advance Transformational AAV Platform
StrideBio, Inc, a US-based company developing novel AAV vectors for in vivo gene therapies announced today that it had closed an oversubscribed Series A Financing Round of $15.7 million.
StrideBio Secures Seed Funding to Advance its Novel AAV Platform
StrideBio, Inc, a US-based company developing novel AAV vectors for in vivo gene delivery applications announced today that it had raised a seed round of capital from Hatteras Venture Partners to help support the ongoing growth of the company.
CRISPR Therapeutics and Casebia Therapeutics Announce Exclusive Development and Option Agreement with StrideBio
CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, and Casebia Therapeutics, a joint-venture established by CRISPR Therapeutics and Bayer AG for developing CRISPR-based therapeutics in select disease areas, today announced they have signed a collaboration agreement with StrideBio, LLC, a US-based company developing novel AAV vectors for in vivo gene delivery applications.